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Abstract
The Ehrlichia muris-like agent (EMLA) is an emerging, tick-transmitted human pathogen that 
occurs in the upper Midwestern United States. Here, we describe the development and validation 
of a p13-based quantitative real-time PCR TaqMan assay to detect EMLA in blood or tissues of 
ticks, humans, and rodents. The primer and probe specificities of the assay were ascertained using 
a large panel of various Ehrlichia species and other members of Rickettsiales. In addition to 
control DNA, both non-infected and EMLA-infected human blood, Mus musculus blood, and Mus 
musculus tissue extracts were evaluated, as were non-infected and EMLA-infected I. scapularis 
and uninfected D. variabilis DNA lysates. The specificity of the probe was determined via real-
time PCR. An EMLA p13 control plasmid was constructed, and serial dilutions were used to 
determine the analytical sensitivity, which was found to be 1 copy per 4 μl of template DNA. The 
sensitivity and specificity of this assay provides a powerful tool for ecological studies involving 
arthropod vectors and their mammalian hosts.
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Introduction
Ehrlichioses are tick-borne diseases caused by obligate intracellular bacteria in the genus 
Ehrlichia that affect various mammals including humans. In the United States, ehrlichiosis 
has historically been caused by infection with Ehrlichia chaffeensis or Ehrlichia ewingii 
(Paddock and Childs 2003). However, in 2009, a new ehrlichial pathogen, designated the 
Ehrlichia muris-like agent (EMLA), was identified in patients and Ixodes scapularis ticks in 
Minnesota and Wisconsin (Pritt et al. 2011). Since the initial report, this pathogen has been 
identified in more than 50 patients, as well as white-footed mice (Peromyscus leucopus) and 
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additional I. scapularis ticks in these states, though there have been no successful efforts to 
identify EMLA outside of Wisconsin and Minnesota to date (Pritt et al. 2011, Castillo et al. 
2014, Wormser and Pritt 2015).
EMLA is genetically most closely related to E. muris, a species of Ehrlichia found in Asia 
and Japan, and may in fact represent a subspecies of E. muris (Wen et al. 1995, Rar et al. 
2008, Rar et al. 2010, Karpathy et al. 2015). Because of this close genetic relationship 
between EMLA and E. muris, molecular detection in research labs has been primarily 
limited to broad range PCR with additional analysis via sequencing or melt curve analysis. 
While this is effective, it is time consuming and generally expensive. The availability of a 
real-time TaqMan PCR assay for specific detection of EMLA and exclusion of E. muris will 
provide a useful tool in both the continued search for EMLA outside of Minnesota and 
Wisconsin as well as ecological studies of EMLA, which are needed to more clearly 
elucidate the natural reservoir and other possible vectors of the pathogen.
Materials and Methods
Design of PCR primers and probe
All available EMLA gene sequences in GenBank were compared to the E. muris AS145T 
sequences. The percent identity of outer membrane protein p13 for the two bacteria is 91%, 
significantly less than that of other loci, and thus this locus was chosen as a good potential 
PCR target for differentiating the two. The EMLA p13 gene sequence (KF523727) was 
aligned with the E. muris strain AS145T p13 sequence (KC595882) using MEGA version 
5.1 software to identify any regions that differ substantially between the two species 
(Tamura et al. 2011). Primers P13-116-F and P13-196-R were designed to take advantage of 
a 12 nucleotide deletion at position 120 of the EMLA p13 gene that is not found in the type 
strain of E. muris (Figure 1). The forward and reverse primers were designed using NCBI's 
Primer-BLAST and NetPrimer (www.premierbiosoft.com) to amplify a 99 bp fragment of 
the EMLA p13 gene. The 25 bp probe P13-147-FAM was then designed to bind the 
amplicon and to have a melting temperature that was 10 °C higher than the primers (Table 
1). Oligonucleotides were synthesized by the Biotechnology Core Facility Branch at CDC.
PCR optimization
DNA extracted from EMLA-infected DH82 cells was used throughout the optimization 
process as template DNA. Temperatures ranging from 55 to 65 °C were tested to determine 
the optimal annealing temperature. The PCR reactions were always conducted in a final 
volume of 25 μl, and the amplified PCR products were visualized by UV lamp in a 1.5% 
agarose gel containing 0.1 μg/ml ethidium bromide.
PCR amplification
The PCR assay was performed in a BioRad CFX 96 thermal cycler using the QuantiTect 
Multiplex PCR Kit (QIAGEN, Valencia, CA). Each 25 μl reaction consisted of 12.5 μl 
QuantiTect Master Mix, 7 μl PCR-grade water, 1 μl of the probe at 5 μM, 0.25 μl each of the 
forward and reverse primers at 20 μM, and 4 μl of template DNA. Cycling conditions were 
as follows: initial denaturation at 95 °C for 15 minutes followed by 45 cycles of 95 °C for 1 
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minute and 60 °C for 1 minute. Fluorescence data was acquired at the end of the annealing 
step of each cycle.
Cloning and sequencing
PCR was used to amplify the p13 region from EMLA template DNA using primers 
P13-116-F and P13-196-R. The amplicon was purified using the Promega Wizard SV Gel 
and PCR Clean-up System (Promega, Madison, WI) and cloned into pCR2.1 using the 
TOPO TA cloning kit (Life Technologies, Grand Island, NY). The cloned products were 
sequenced in both directions and assembled using Sequencher 5.1 (Gene Codes, Ann Arbor, 
MI) to verify insertion of the p13 amplicon.
Specificity and sensitivity
To characterize the specificity of the PCR reaction, the primers and probe were used to 
analyze positive controls from cell culture for other ehrlichial species, as well as DNA of 
cell culture samples of other members of the order Rickettsiales. In addition to control DNA, 
non-infected and EMLA-infected Mus musculus blood and tissue extracts were screened, as 
were non-infected I. scapularis and D. variabilis DNA lysates and EMLA-infected I. 
scapularis lysates, all of which were previously tested using established 16S primers 
ECHSYBR-F and ECHSYBR-R, which detect all species within the family 
Anaplasmataceae (Table 2) (Li et al. 2002).
All Rickettsiales in Table 2 are controls from cell culture that were verified using a hemi-
nested ompA assay and subsequently sequenced for species confirmation (Regnery et al. 
1991, Roux et al. 1996). Anaplasmataceae culture samples in Table 2 were verified using 
16S primers and sequencing, as were Neoehrlichia lotoris (obtained from the blood of a 
raccoon), and Neoehrlichia mikurensis (obtained from the blood a patient in Europe) (Li et 
al. 2002). Human cells came from the American Type Culture Collection [ATCC] 
(Manassas, VA). All Mus musculus and Ixodes scapularis samples from Table 2 were 
generated at CDC during the course of mouse transmission and co-feeding experiments with 
EMLA in work that is not yet published.
Further evaluation was performed using a panel of 55 blinded specimens provided by the 
Division of Clinical Microbiology at Mayo Clinic in Minnesota, comprising DNA extracts 
from 41 questing adult I. scapularis ticks, 13 human patients (EDTA whole blood), and 1 E. 
muris cell culture isolate. Ticks were collected from Camp Phillips, WI in October 2013 and 
June 2014 and were extracted using either a BioLine (BioLine, London, UK) or MagNA 
Pure LC Total Nucleic Acid Isolation Kit (MagNA Pure Instrument, Roche Applied 
Science). All patient samples and the one cell culture sample were also extracted using the 
MagNA Pure kit. In this panel, 16 were positive for EMLA, 9 were positive for A. 
phagocytophilum, 3 were positive for E. chaffeensis, 1 was positive for E. muris, 1 was 
positive for E. ewingii, and 25 were negative for all Ehrlichia species using a previously 
reported assay at Mayo Clinic (Table 3) (Bell and Patel 2005, Castillo et al. 2014).
Included with all PCR reactions were negative controls without DNA template as well as 
positive control reactions containing plasmid DNA with the EMLA p13 insert. Primer 
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specificity was further examined by resolving completed PCR reactions on 1.5% agarose 
gels to check for amplicons.
To determine the sensitivity of the assay, control plasmid DNA concentration was 
determined using a Qubit 2.0 fluorometer (Life Technologies, Grand Island, NY). Copy 
number was calculated based on concentration of DNA, and serial dilutions were prepared 
to attain copy numbers of 105, 104, 103, 102, 10, 5, 2.5, and 1 per 4 μl of DNA. This dilution 
series was screened on the BioRad CFX96 Touch thermal cycler to create a standard curve 
for determining the limit of detection (Figure 2).
Results and Discussion
For all controls listed in Table 2, DNA amplification was detected only when EMLA-
positive controls were used as template DNA. Of the 55 tick and patient samples sent from 
Mayo Clinic, all 39 EMLA-negative samples were also negative with the p13 assay. 15 of 
the 16 EMLA-positive samples were detected with the p13 assay. The one EMLA-positive 
tick sample that was negative using the p13 assay was also screened and determined to be 
negative with a nested PCR assay targeting the gltA gene of E. muris and EMLA 
(Tamamoto et al. 2007, Telford III et al. 2011). Because this tick sample also tested negative 
with the nested gltA assay, it is possible that the DNA in the sample had degraded since the 
time it was tested at Mayo Clinic. Further examination of this sample by the Mayo Clinic 
established real-time assay may have resolved this question, but a lack of sample volume 
prevented further testing. The analytical sensitivity and limit of detection of the assay was 
determined to be 1 copy of plasmid DNA with an R2 of the standard curve for the dilution 
series of 0.995. Because the assay detected 1 copy of plasmid DNA at a threshold cycle of 
39, the cutoff for future use of the assay was determined to be 40 cycles.
Conclusions
As efforts continue to determine the geographic range, natural reservoir, and arthropod 
vector of EMLA, more efficient molecular detection methods for the pathogen are 
necessary. This report describes the successful development, optimization, and performance 
testing of a p13 real-time PCR assay for the detection of EMLA in ticks, humans, and 
mammals. The sensitive and specific PCR developed here provides a powerful tool for use 
in ecological studies of EMLA as well as in the continued search to find the pathogen 
outside of the upper Midwest.
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Figure 1. 
Primer and probe alignments for the a. forward primer, b. reverse primer, and c. probe. 
Boxes highlight areas of the primers or probe that are different between E. muris AS145T 
and EMLA.
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Figure 2. 
Standard curve from sensitivity testing of assay.
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Table 1
Primer and probe sequences.
Primers/Probe Sequences (5'-3') Melting Temperature Product Size
p13-116-F AAA GAG TCA GTG TTG ATC CG 52.1 °C
p13-196-R CAA TGA TGA TAC TGC GAA CA 52.24 °C 99 bp
p13-147-FAM TTG CTA TTG GCT GGG TTT TTT AGT 61.88 °C
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Table 2
List of controls used for specificity testing.
Control Templates Tested
A. phagocytophilum strain USG3 R. parkeri strain HMAC
E. canis strain Jake R. peacockii strain Rustic
E. chaffeensis strain Arkansas R. sibirica strain SE
E. muris strain AS145 R. slovaca strain D
R. africae strain Z9-Hu R. typhi strain Willmington PP
R. akari strain HS CWPP Neoehrlichia lotoris
R. amblyommi strain GAT8-2 Neoehrlichia mikurensis
R. australis strain JC-2 O. tsutsugamushi strain Karp PP
R. canadensis strain McKiel 24 I. scapularis-uninfected
R. conorii strain Malish 7 I. scapularis-EMLA infected*
R. felis D. variabilis-uninfected
R. helvetica strain C9P9 Human Aorta Cells
R. honei strain FSF Human Lung Endothelial Cells
R. phillipii strain 364D Human Microvascular Endothelial Cells
R. prowazekii strain Breinl Human Umbilical Endothelial Cells
R. rhipicephali strain 12T E. coli strain INVαF'
R. rickettsii strain AZ-1 B. elizabethae strain F9251
R. rickettsii strain BSF Rab 1 B. henselae strain Houston-1
R. rickettsii strain Colombia B. vinsonii strain Berkhoffii
R. rickettsii strain Costa Rica EMLA-negative Mus musculus blood
R. rickettsii strain HLP #2 EMLA-infected Mus musculus blood*
R. rickettsii strain OSU 84-21c EMLA-negative Mus musculus lung
R. rickettsii strain Sheila Smith EMLA-infected Mus musculus lung*
R. massiliiae strain Mtu1 EMLA-negative Mus musculus spleen
R. montanensis strain OSU 85–930 EMLA-infected Mus musculus spleen*
All samples were negative with the p13 assay except those marked with an (*), which were controls positive for EMLA.
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Table 3
Summary of Mayo Clinic blind samples results
Host / Pathogen (number of samples) Number Positive by p13 Assay % Concordance with Conventional PCR
Human / EMLA (8) 8 100
Human / E. chaffeensis (3) 0 100
Human / E. ewingii (1) 0 100
Human / No agent (1) 0 100
I. scapularis / EMLA (8) 7 88
I. scapularis / A. phagocytophilum (9) 0 100
I. scapularis / No agent (24) 0 100
E. muris (1) 0 100
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